摘要
目的分析体外诱导的NY-ESO-1特异性杀伤性T淋巴细胞对稳定表达NY-ESO-1蛋白的肝细胞性肝癌(hepatocellular carcinoma,HCC)细胞系的杀伤效应,为进一步分析NY-ESO-1蛋白作为疫苗用于治疗HCC的可能性提供实验支持。方法从HLA-A2阳性的肝癌患者体内分离出外周血单个核细胞,用NY-ESO-1肽段体外诱导特异性杀伤性T淋巴细胞,并通过酶联免疫斑点法分析特异性杀伤性T淋巴细胞对稳定表达NY-ESO-1蛋白的HCC细胞系HepG2细胞的杀伤效应。结果转染了NY-ESO-1的HepG2细胞(HLA-A2+)可有效地被NY-ESO-1157-165抗原肽诱导的特异性CD8+T淋巴细胞所识别。效应细胞中大量GrB的释放表明其对稳定转染了NY-ESO-1基因的HepG2细胞有很强的杀伤作用。结论HepG2细胞中表达的NY-ESO-1蛋白可被此肝癌细胞有效地加工处理,而且HLA-A2限制性的抗原肽NY-ESO-1157-165也可被有效地提呈到细胞表面,从而被效应T细胞所识别。
Objective: To analyze the effect of an NY-ESO-1 expressing HCC cell line by NY-ESO-lb specific CD8 ^+ T cells in vitro induced by HLA-A2 Restricted NY-ESO-1 b peptide and to further analyze the possibility of NY-ESO-1 as a vaccine in HCC treatment. Methods: Peripheral blood mononuclear cells (PBMCs) were obtained from an HLA-A2^+ HCC patient and NY-ESO-1 specific CD8 ^+ T cells were in vitro induced by HLA-A2 Restricted NY-ESO-1 b peptide. Next we estimated the effect that NY-ESO-1 specific CD8 ^+ T cells recognized and killed NY-ESO-1 expressing HepG2 ceils by enzyme-linked immunospot (ELISPOT). Results: These in vitro induced NY-ESO-lb specific CD8 ^+ T cells could recognize HepG2 cells stably transfected with NY-ESO-1 in both IFN-γ and Granzyme B ELISPOT assays. And the data also showed that NY-ESO-1 specific CD8 ~ T cells could efficiently kill NY-ESO-1 expressing HepG2 cells. Conclusion: NY-ESO-1 protein can be processed by HCC cells, and that HLA-A2 restricted NY- ESO-lb peptide (157-165) can also be presented on the surfaces of cells and recognized by NY-ESO-lb specific CD8 ^+ T cells in vitro induced.
出处
《北京大学学报(医学版)》
CAS
CSCD
北大核心
2005年第6期565-568,共4页
Journal of Peking University:Health Sciences
基金
国家重点基础研究发展规划项目基金(G1999053904)
北京市自然科学基金(7001002)
国家高技术研究发展计划专项经费(2001AA217151)资助~~
关键词
癌
肝细胞
抗原
肿瘤
肿瘤细胞
培养的
酶联免疫吸附测定
Carcinoma, hepatocellular
Antigens, neoplasm
Tumor ceils, cultured
Enzyme-linked immunosorbent assay